RU1782598C - Anticolibacterial composition simofin-2 for newborn calves - Google Patents
Anticolibacterial composition simofin-2 for newborn calvesInfo
- Publication number
- RU1782598C RU1782598C SU904906841A SU4906841A RU1782598C RU 1782598 C RU1782598 C RU 1782598C SU 904906841 A SU904906841 A SU 904906841A SU 4906841 A SU4906841 A SU 4906841A RU 1782598 C RU1782598 C RU 1782598C
- Authority
- RU
- Russia
- Prior art keywords
- composition
- simofin
- anticolibacterial
- newborn calves
- newborn
- Prior art date
Links
Landscapes
- Feed For Specific Animals (AREA)
Description
ших животных не выделен возбудитель ко- либактериоза.the causative agent of colibacillosis was not isolated in these animals.
В опытной группе 3 (вводилс состав 1 в дозе 2 мл) заболеваемость новорожденных тел т составила 60%, падеж 10% и у павших животных не выделен возбудитель колибактериоза,In experimental group 3 (composition 1 at a dose of 2 ml was administered), the incidence of newborn m-t was 60%, mortality 10%, and the causative agent of colibacteriosis was not isolated in the dead animals.
В опытной группе 4 (вводилс состав 1 в дозе 4 мл) заболеваемость составила 60%, падеж 10%, но препарат оказывал раздра- жающее воздействие.In experimental group 4 (composition 1 at a dose of 4 ml was administered), the incidence was 60%, mortality 10%, but the drug had an irritating effect.
В опытной группе 5 (вводилс состав 2 в дозе 1 мл) заболеваемость новорожденных тел т составила 45% и протекала в легкой форме, падеж отсутствовал, возбудитель колибактериоза не выделен.In experimental group 5 (composition 2 was administered at a dose of 1 ml), the incidence of neonatal bodies was 45% and proceeded in a mild form, there was no death, the causative agent of colibacteriosis was not isolated.
В опытной группе 6 (вводилс состав 2 в дозе 2 мл) заболеваемость новорожденных тел т составила 40% и протекала в лег- кой форме, падеж отсутствовал, возбудитель калибактериоза не выделен.In experimental group 6 (composition 2 was administered at a dose of 2 ml), the incidence of neonatal bodies was 40% and proceeded in a mild form, there was no death, and the causative agent of calibacteriosis was not isolated.
. В опытной группе 7 (вводилс состав 2 в дозе 4 мл) заболеваемость новорожденных тел т составл ла 40% и протекала в легкой форме, падеж отсутствовал, препа- рат оказывал раздражающее воздействие на ткани.. In experimental group 7 (composition 2 was administered at a dose of 4 ml), the incidence of newborn bodies was 40% and proceeded in a mild form, there was no death, the drug had an irritating effect on tissues.
В опытной группе 8 (вводилс препарат 3 в дозе 1 мл) заболеваемость новорожден- ныхтел т составила 50%, падеж 10%, у павших животных не выделен возбудитель колибактериоза .In experimental group 8 (drug 3 was administered at a dose of 1 ml), the incidence of newborns was 50%, mortality 10%, and the causative agent of colibacteriosis was not isolated in the dead animals.
В опытной группе 9 (вводилс препарат 3 в дозе 2 мл) заболеваемость новорождённых тел т составила 50%, падеж 10%, у павших животных не выделен возбудитель колибактериоза.In experimental group 9 (drug 3 was administered at a dose of 2 ml), the incidence of newborn t was 50%, mortality 10%, and the causative agent of colibacteriosis was not isolated in the dead animals.
В опытной группе 10 (вводилс препарат 3 в дозе 4 мл) заболеваемость новорожденных тел т составила 50%, падеж 10%, у павших животных возбудитель колибактериоза не выделен, препарат оказал раздражающее воздействие на ткани.In experimental group 10 (drug 3 was administered at a dose of 4 ml), the incidence of neonatal bodies was 50%, mortality 10%, the causative agent of colibacteriosis was not isolated in the dead animals, and the drug had an irritating effect on the tissues.
Таким о.бразом изобретение позвол ет снизить падеж новорожденных тел т на 8- 20% и заболеваемость желудочно-кишечными заболевани ми на 15-40%.Thus, the invention makes it possible to reduce the death rate of newborn calves by 8-20% and the incidence of gastrointestinal diseases by 15-40%.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SU904906841A RU1782598C (en) | 1990-10-30 | 1990-10-30 | Anticolibacterial composition simofin-2 for newborn calves |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SU904906841A RU1782598C (en) | 1990-10-30 | 1990-10-30 | Anticolibacterial composition simofin-2 for newborn calves |
Publications (1)
Publication Number | Publication Date |
---|---|
RU1782598C true RU1782598C (en) | 1992-12-23 |
Family
ID=21558040
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SU904906841A RU1782598C (en) | 1990-10-30 | 1990-10-30 | Anticolibacterial composition simofin-2 for newborn calves |
Country Status (1)
Country | Link |
---|---|
RU (1) | RU1782598C (en) |
-
1990
- 1990-10-30 RU SU904906841A patent/RU1782598C/en active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR930702022A (en) | Treatment or prevention of type 1 diabetes by oral administration of insulin | |
RU95107881A (en) | Pharmaceutical composition for allergic disease treatment, method of antihistamine treatment, use of composition for medicinal preparation preparing | |
DE69127470D1 (en) | REINFORCING REGULATION OF AUTOIMMUNE DISEASES BY ORAL OR ENTERAL ADMINISTRATION OF AUTOANTIGENS | |
MY102565A (en) | Novel derivatives of guanine | |
PT809512E (en) | Non-inorganic Saline Pharmaceutical Solutions for Endon Vasal Administration of a Calcitonin | |
SE8105561L (en) | USE OF PYRIDOXIN-ALFA-KETOGLUTARATE IN PROPHYLAX OF HYPERMOOLIC ACIDEMA | |
DK157482A (en) | GALENIC PREPARATION CONTAINING GALLOPAMIL OR VERAPAMIL AND PROCEDURES FOR PREPARING IT | |
CA1297033C (en) | Use of carboxylic acid amides for treating inflammations | |
ES8306483A1 (en) | Tricyclic ethers, processes for their preparation and their use as medicaments. | |
RU1782598C (en) | Anticolibacterial composition simofin-2 for newborn calves | |
BG101709A (en) | New applications of lysozyme dimer | |
US4474759A (en) | Method of treating bacterial, viral or parasitic diseases | |
US4378351A (en) | Methods of treating bacterial, viral or parasitic diseases | |
KR890012942A (en) | 5-substituted ornithine derivatives | |
US3873709A (en) | Method of treating psychosis | |
US4469678A (en) | Method of treating bacterial, viral or parasitic diseases | |
KR920700626A (en) | Drugs for the treatment of toxoplasma disease | |
US4452781A (en) | Method of treating bacterial viral or parasitic diseases | |
DE2706841C2 (en) | ||
SE8200748L (en) | THERAPEUTIC AGENT | |
RU2228195C2 (en) | Pharmaceutical composition eliciting antiviral activity with respect to herpes viruses | |
EP0383481A3 (en) | Anesthetic oral compositions | |
US4378350A (en) | Method of treating bacterial, viral or parasitic diseases | |
US4378349A (en) | Methods of treating bacterial, viral or parasitic diseases | |
JPS58146509A (en) | Medicinal composition |